- Home
- ABUS
as 07-26-2024 4:00pm EST
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Upcoming Earnings Alert:
Get ready for potential market movements as Arbutus Biopharma Corporation ABUS prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WARMINSTER |
| Market Cap: | 596.3M | IPO Year: | N/A |
| Target Price: | $4.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.69 - $3.98 | Next Earning Date: | 08-01-2024 |
| Revenue: | $12,986,000 | Revenue Growth: | -60.80% |
| Revenue Growth (this year): | -62.9% | Revenue Growth (next year): | -10.51% |
Stock Insider Trading Activity of Arbutus Biopharma Corporation (ABUS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sims Karen | ABUS | Chief Medical Officer | Feb 1 '24 | Sell | $2.31 | 4,358 | $10,077.88 | 125,542 | SEC Form 4 |
| HASTINGS DAVID C | ABUS | Chief Financial Officer | Feb 1 '24 | Sell | $2.31 | 9,593 | $22,183.81 | 181,907 | SEC Form 4 |
| Sofia Michael J. | ABUS | Chief Scientific Officer | Feb 1 '24 | Sell | $2.31 | 9,982 | $23,083.38 | 1,485,121 | SEC Form 4 |
| McElhaugh Michael J. | ABUS | Interim President & CEO | Feb 1 '24 | Sell | $2.31 | 10,164 | $23,504.25 | 1,504,793 | SEC Form 4 |
Latest Arbutus Biopharma Corporation News
ABUS Breaking Stock News: Dive into ABUS Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Zacks
a month ago
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
MT Newswires
2 months ago
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial
GlobeNewswire
2 months ago
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
GlobeNewswire
2 months ago
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
GlobeNewswire
2 months ago
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
GlobeNewswire
2 months ago
Arbutus to Participate in Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
Arbutus to Present Imdusiran Data at EASL Congress 2024
Compare ABUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABUS Arbutus Biopharma Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.